DOCSLIB.ORG

An Investigation Into the Pharmacology of the Ghrelin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Investigation Into the Pharmacology of the Ghrelin An Investigation into the Pharmacology of the Ghrelin Receptor Kirstie Ann Bennett (BSc Hons) Submitted in fulfilment of the requirements for the Degree of Doctor of Philosophy Department of Neuroscience and Molecular Pharmacology Faculty of Biomedical and Life Sciences University of Glasgow August 2009 2 Abstract The ghrelin receptor (GRLN-R) was cloned in 1996 after the discovery that a series of synthetic growth hormone-releasing compounds (the growth hormone secretagogues) acted through a receptor distinct from the growth hormone-releasing hormone receptor. In 1999 the endogenous ligand of the receptor, ghrelin, was discovered. As well as stimulating growth hormone release, ghrelin has been shown to be involved in many other processes such as appetite stimulation and the regulation of energy homeostasis, making the ghrelin/GRLN-R system an attractive pharmaceutical target for the treatment of disorders such as growth hormone deficiency, cachexia and obesity. The GRLN-R displays a high level of ligand-independent (constitutive) activity and has been suggested to couple to Gαq/11 , G αi/o , Gαs and G α12/13 G protein pathways, although little is known about the signalling of ghrelin and the growth hormone secretagogues in all but the G αq/11 pathway. Two of the growth hormone secretagogues, GHRP-6 and L-692,429, have been described as ‘ago-allosteric modulators’ of the GRLN-R as, when co-administered with ghrelin, GHRP-6 and L-692,429 were reported to act both as co-agonists (increasing the efficacy of the ghrelin response) and as negative or positive (respectively) regulators of the potency of ghrelin. This study sought to investigate the pharmacology of the GRLN-R through the Gαi/o pathway. 35 [ S]GTP γS binding assays were used to measure activation of the G αi/o pathway, demonstrating that GHRP-6, L-692,585 (a commercially available analogue of L-692,429) and a third growth hormone secretagogues, MK-677, acted with higher efficacy than ghrelin. At least in the system tested, upon co-administration with ghrelin each of the growth hormone secretagogues acted in a simple competitive fashion with ghrelin. Radioligand binding experiments showed that the dissociation kinetics of [His[ 125 I]]- ghrelin from the GRLN-R were not altered by co-administration of the growth hormone secretagogues. Fitting data to a modified operational model of allosterism demonstrated that GHRP-6, L-692,585 and MK-677 were not ago-allosteric modulators of the GRLN-R but simple orthosteric agonists. In order to further examine the receptor-specific effects of ghrelin and the growth hormone secretagogues, a Flp-In™ T-REx™ HEK293 cell line expressing the GRLN-R was constructed. [35 S]GTP γS binding assays confirmed that the GRLN-R was constitutively active through both the G αq/11 and G αi/o pathways, demonstrated by an increase in [35 S]GTP γS loading upon receptor expression which could be reduced by the 3 administration of the GRLN-R inverse agonist SPA. Upon expression of the GRLN-R a considerable level of cell detachment was observed with the remaining cells appearing rounded compared to parental HEK293 cells, an affect that appeared to be mediated by the constitutive activity of the receptor. 35 35 In contrast to the [ S]GTP γS assays used to measure activation of G αi/o, [ S]GTP γS assays with a G αq-immunoprecipitation step demonstrated that the growth hormone secretagogues acted with equal efficacies to that of ghrelin, demonstrating functional selectivity at the GRLN-R. Intact cell assays were also used to measure Gαq/11 and G αi/o responses, however, a G αi/o -mediated response could not be measured in cAMP accumulation assays, suggesting that the GRLN-R could signal via activation of G αo but not G αi1-3. Although the activation of the G αs pathway by the GRLN-R remains controversial, in this study ghrelin and the growth secretagogues could evoke a G αs-mediated cAMP response (although L-692,585 acted with a lower efficacy than ghrelin). Finally, two naturally occurring missense mutations of the GRLN-R (A204E in the second extracellular loop and I134T in the third transmembrane helix) were analysed to investigate whether these mutations led to retention of the receptor within the endoplasmic reticulum and to investigate whether the mutations affected the ability of the GRLN-R to signal to the growth hormone secretagogues. The A204E mutation caused partial retention of the GRLN-R within the endoplasmic reticulum, whilst receptor that was transported to the plasma membrane did not display any measurable constitutive activity. In contrast, the I134T mutation did not alter receptor localisation, nor did it have any effect on the constitutive or ligand-induced activation of the GRLN-R, however, it appeared to lower the efficacy of the inverse agonist SPA. 4 Contents 1 Introduction .............................................................................................................19 1.1 Introduction to ghrelin and the ghrelin receptor ................................................19 1.2 Ghrelin tissue distribution.................................................................................24 1.3 GRLN-R tissue distribution..............................................................................24 1.4 Biological actions of the GHs-R1b ...................................................................25 1.5 Biological actions of ghrelin, the growth hormone secretagogues and the GRLN- R .........................................................................................................................25 1.5.1 GH release................................................................................................25 1.5.2 Appetite and energy homeostasis ..............................................................26 1.5.3 Other ghrelin/GRLN-R effects..................................................................28 1.5.4 Existence of receptors for ghrelin/the growth hormone secretagogues other than the GRLN-R.....................................................................................................29 1.6 Ghrelin-null or GRLN-R-null models...............................................................31 1.7 Clinical trials and therapeutic potential of GRLN-R agonists/antagonists..........33 1.7.1 Cachexia...................................................................................................33 1.7.2 GH deficiency...........................................................................................34 1.7.3 Obesity.....................................................................................................35 1.8 GPCR structure ................................................................................................36 1.8.1 Introduction to the G protein-coupled receptor superfamily.......................36 1.8.2 GPCR classification..................................................................................36 1.8.3 GPCR crystal structure .............................................................................38 1.8.4 GRLN-R structure ....................................................................................39 1.8.5 Residues contributing to the constitutive activity of the GRLN- R ............43 1.8.6 Ligand-binding pocket of the GRLN-R.....................................................45 1.8.7 Ligand-binding pocket for SPA ................................................................46 1.9 Dimerisation.....................................................................................................48 1.9.1 Introduction to dimerisation......................................................................48 1.9.2 Dimerisation of the GRLN-R....................................................................49 1.10 GPCR signalling...............................................................................................50 1.10.1 Introduction to G proteins .........................................................................50 1.10.2 G protein coupling of the GRLN-R ...........................................................51 1.10.3 G protein-independent signalling ..............................................................55 1.10.4 Desensitisation and endocytosis................................................................56 1.10.5 Constitutive activity..................................................................................60 1.10.6 Allosterism...............................................................................................65 1.11 Project aims......................................................................................................67 2 Materials and methods .............................................................................................68 2.1 General reagents, enzymes and kits ..................................................................68 2.2 Antibodies and antisera ....................................................................................70 2.3 Pharmacological compounds ............................................................................71 2.4 Radiochemicals................................................................................................72 2.5 Tissue culture disposables and reagents ............................................................72 2.6 Buffers and solutions........................................................................................73 2.6.1 Molecular biology buffers and solutions ...................................................73
Load more

Recommended publications
  • New Developments in Prokinetic Therapy for Gastric Motility Disorders
    REVIEW published: 24 August 2021 doi: 10.3389/fphar.2021.711500 New Developments in Prokinetic Therapy for Gastric Motility Disorders Michael Camilleri* and Jessica Atieh Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT4 agonists, dopaminergic D2/3 antagonists, neurokinin NK1 antagonists, and ghrelin agonist. Novel Edited by: targets with potential to improve gastric motor functions include the pylorus, macrophage/ Jan Tack, inflammatory function, oxidative
    [Show full text]
  • Drug Testing Program
    DRUG TESTING PROGRAM Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING CONTENTS 1. DRUG-FREE COMPETITION 2. ATHLETE CONSENT 3. DRUG TESTING 4. IN-COMPETITION/OUT-OF-COMPETITION DRUG TESTING 5. REGISTERED ATHLETE TESTING POOL (OUT-OF-COMPETITION DRUG TESTING) 6. REMOVAL FROM TESTING POOL/RETIREMENT 6A. REMOVAL FROM TESTING POOL/WATCH LIST 7. TESTING POOL REQUIREMENTS FOLLOWING A SANCTION 8. DRUG TEST NOTIFICATION AND ADMINISTRATION 9. SPECIMEN ANALYSIS 10. REPORTING RESULTS 11. DRUG TESTING POLICY VIOLATIONS 12. ENFORCEMENT/SANCTIONS 13. APPEALS PROCESS 14. LEADERBOARD DISPLAY 15. EDUCATION 16. DIETARY SUPPLEMENTS 17. TRANSGENDER POLICY 18. THERAPEUTIC USE EXEMPTION APPENDIX A: 2020-2021 CROSSFIT BANNED SUBSTANCE CLASSES APPENDIX B: CROSSFIT URINE TESTING PROCEDURES - (IN-COMPETITION) APPENDIX C: TUE APPLICATION REQUIREMENTS Drug Testing Policy V4 Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. [ 2 ] 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING 1. DRUG-FREE COMPETITION As the world’s definitive test of fitness, CrossFit Games competitions stand not only as testaments to the athletes who compete but to the training methodologies they use. In this arena, a true and honest comparison of training practices and athletic capacity is impossible without a level playing field. Therefore, the use of banned performance-enhancing substances is prohibited. Even the legal use of banned substances, such as physician-prescribed hormone replacement therapy or some over-the-counter performance-enhancing supplements, has the potential to compromise the integrity of the competition and must be disallowed. With the health, safety, and welfare of the athletes, and the integrity of our sport as top priorities, CrossFit, LLC has adopted the following Drug Testing Policy to ensure the validity of the results achieved in competition.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Fully Automated Dried Blood Spot Sample Preparation Enables the Detection of Lower Molecular Mass Peptide and Non-Peptide Doping Agents by Means of LC-HRMS
    Analytical and Bioanalytical Chemistry (2020) 412:3765–3777 https://doi.org/10.1007/s00216-020-02634-4 RESEARCH PAPER Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS Tobias Lange1 & Andreas Thomas1 & Katja Walpurgis1 & Mario Thevis1,2 Received: 10 December 2019 /Revised: 26 March 2020 /Accepted: 31 March 2020 # The Author(s) 2020 Abstract The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone–releasing peptides (GHRPs), argu- ably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters.
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Effect of Ghrelin Receptor Ligands on Proliferation of Prostate Stromal Cells and on Smooth Muscle Contraction in the Human Prostate
    Aus der Urologischen Klinik und Poliklinik der Ludwig-Maximilians-Universität München Direktor: Prof. Dr. Christian G. Stief Effect of ghrelin receptor ligands on proliferation of prostate stromal cells and on smooth muscle contraction in the human prostate Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München vorgelegt von Xiaolong Wang aus Wuhan, China 2020 Mit Genehmigung der Medizinischen Fakultät der Universität München Berichterstatter: Prof. Dr. rer. nat. Martin Hennenberg Mitberichterstatter: PD Dr. Heike Pohla Prof. Dr. Wolf Mutschler Dekan: Prof. Dr. med. dent. Reinhard Hickel Tag der mündlichen Prüfung: 20.02.2020 1. Introduction ........................................................................................ 1 1.1 Definition of LUTS .......................................................................... 1 1.2 Epidemiology, etiology and nature history of LUTS ................... 2 1.3 Pathogenesis of LUTS suggestive to BPH ..................................... 4 1.3.1 Age .............................................................................................. 6 1.3.2 Inflammation ............................................................................... 6 1.3.3 Sex hormones .............................................................................. 7 1.3.4. Metabolic factors ....................................................................... 7 1.3.5 Other urologic diseases associated with LUTS .......................... 9
    [Show full text]
  • ( 12 ) United States Patent
    US010317418B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,317 ,418 B2 Goosens (45 ) Date of Patent: * Jun . 11 , 2019 (54 ) USE OF GHRELIN OR FUNCTIONAL 7 , 479 ,271 B2 1 / 2009 Marquis et al . GHRELIN RECEPTOR AGONISTS TO 7 ,632 , 809 B2 12 / 2009 Chen 7 ,666 , 833 B2 2 /2010 Ghigo et al. PREVENT AND TREAT STRESS -SENSITIVE 7 , 901 ,679 B2 3 / 2011 Marquis et al . PSYCHIATRIC ILLNESS 8 ,013 , 015 B2 9 / 2011 Harran et al . 8 ,293 , 709 B2 10 /2012 Ross et al . (71 ) Applicant: Massachusetts Institute of 9 ,724 , 396 B2 * 8 / 2017 Goosens A61K 38 /27 9 , 821 ,042 B2 * 11 /2017 Goosens .. A61K 39/ 0005 Technology , Cambridge , MA (US ) 10 , 039 ,813 B2 8 / 2018 Goosens 2002/ 0187938 A1 12 / 2002 Deghenghi (72 ) Inventor : Ki Ann Goosens, Cambridge , MA (US ) 2003 / 0032636 Al 2 /2003 Cremers et al. 2004 / 0033948 Al 2 / 2004 Chen ( 73 ) Assignee : Massachusetts Institute of 2005 / 0070712 A1 3 /2005 Kosogof et al. Technology , Cambridge , MA (US ) 2005 / 0148515 Al 7/ 2005 Dong 2005 / 0187237 A1 8 / 2005 Distefano et al. 2005 /0191317 A1 9 / 2005 Bachmann et al. ( * ) Notice : Subject to any disclaimer , the term of this 2005 /0201938 A1 9 /2005 Bryant et al. patent is extended or adjusted under 35 2005 /0257279 AL 11 / 2005 Qian et al. U . S . C . 154 ( b ) by 0 days. 2006 / 0025344 Al 2 /2006 Lange et al. 2006 / 0025566 A 2 /2006 Hoveyda et al. This patent is subject to a terminal dis 2006 / 0293370 AL 12 / 2006 Saunders et al .
    [Show full text]
  • Assessment Report
    15 November 2018 EMA/CHMP/845216/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Macimorelin Aeterna Zentaris International non-proprietary name: macimorelin Procedure No. EMEA/H/C/004660/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.1. Epidemiology .................................................................................................... 8 2.1.2. Aetiology and pathogenesis ...............................................................................
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • Growth Hormone Secretagogues: History, Mechanism of Action and Clinical Development
    Growth hormone secretagogues: history, mechanism of action and clinical development Junichi Ishida1, Masakazu Saitoh1, Nicole Ebner1, Jochen Springer1, Stefan D Anker1, Stephan von Haehling 1 , Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany Abstract Growth hormone secretagogues (GHSs) are a generic term to describe compounds which increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS‐R), whose natural ligand is ghrelin, and agonists of the growth hormone‐releasing hormone receptor (GHRH‐R), to which the growth hormone‐ releasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosisg of GH deficiency, which causes growth retardation, gastrointestinal dysfunction and altered body composition, in parallel with extensive research to identify GHRH, GHS‐R and ghrelin. This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials. Furthermore, we will highlight the publicly disclosed clinical trials regarding GHSs. Address for correspondence: Corresponding author: Stephan von Haehling, MD, PhD Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany Robert‐Koch‐Strasse 40, 37075 Göttingen, Germany, Tel: +49 (0) 551 39‐20911, Fax: +49 (0) 551 39‐20918 E‐mail: [email protected]‐goettingen.de Key words: GHRPs, GHSs, Ghrelin, Morelins, Body composition, Growth hormone deficiency, Received 10 September 2018 Accepted 07 November 2018 1. Introduction testing in clinical trials. A vast array of indications of ghrelin receptor agonists has been evaluated including The term growth hormone secretagogues growth retardation, gastrointestinal dysfunction, and (GHSs) embraces compounds that have been developed altered body composition, some of which have received to increase growth hormone (GH) release.
    [Show full text]